Gastroenterology: Fecal microbiome transplantation treatment of recurrent refractive Clostridium difficile infection is better than fidamycin

Fecal microbiome transplantation (FMT) is recommended for the treatment of recurrent Cdifficile infection (rCDI)We conducted a single-center randomized trial to compare the efficacy of FMT with non-damycin and vancomycinwe studied rCDI continuous adult patients at a gastroenterology clinic in Denmark from 5 April 2016 to 10 June 2018Patients were randomly assigned to a group that received FMT, applied through colonoscopy or nasal tubes, received vancomycin (125 mg 4 times/day; FMTV; n; 24), and 10 days later, non-dakmycin (200 mg 2 times/day; n s 24), or 10 days after receiving vancomycin (125 mg 4 times/day; n s 16)Patients with rCDI after this procedure and those who could not be randomly assigned to the group were given rescue FMTvThe main outcome was negative in the polymerase chain reaction test of the clinical resolution and the polymerase chain reaction of the hard shuttle spore (CD) toxin after 8 weeks of assigned treatmentSecondary endpoints include clinical resolution at week 8results showed that all 64 patients received assigned treatmentClinical remission and CD test results were observed in 17 patients (71%), 8 patients (33%) and 3 patients (19%; FMTv vs nondazomycin PClinical resolution was observed in 22 patients who were given FMTv (92%), 10 patients who were given fethromycin (42%) and 3 patients who gave vancomycin (19%; P - .0002; P .0001; PResults There was no significant difference between patients receiving FMTv as initial treatment and patients receiving rescue FMTvOne case of serious adverse events may be related to FMTvin a randomized trial of rCDI patients, we found that FMTv combinations were superior to non-dasopin or vancomycin at the end of clinical and microbiological or purely clinical solutions